|
|
| From Proof To Promise: The Future Of Genome Editing Therapeutics | Genome editing is advancing rapidly from laboratory innovation to clinical reality, but success depends on more than editing efficiency alone. Explore expert perspectives on guide RNA design, targeted delivery, off-target assessment, manufacturing scalability, quality control, and evolving regulatory expectations. Learn how these technologies and strategies are shaping the next generation of CRISPR therapeutics. Learn more. |
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | The biopharmaceutical's “Valley of Death” is entered through a desert of dwindling funding. Chief Editor Louis Garguilo talks with two consultants on avoiding financial failure when outsourcing development and manufacturing. The many contributing factors for failure may have a common denominator: Project Management is an overlooked financial savior. | |
|
|
|
By Jeffrey S. Buguliskis, Ph.D., Deputy Chief Editor, Outsourced Pharma | Effective sponsor–CDMO collaboration relies on clear communication, shared expectations, and proactive problem-solving. In this episode, guest panelists Stella Vnook, Co-founder and Executive Board Chair, Kaida BioPharma, and Allison Vavala, Senior Director for Business Development, Flamma Group, explore what makes these operating relationships work. The discussion covers building strong day-to-day partnerships, establishing practical meeting cadences, and setting transparent goals from the start. The panel also takes a fun look at common industry phrases like "we need flexibility on timelines" and "can you just take a quick look?" in order to help sponsors and CDMOs better align, prevent miscommunication, and solve technical challenges jointly. | |
|
|
|
By Jeffrey S. Buguliskis, Ph.D., Deputy Chief Editor, Outsourced Pharma | From formulation and packaging to partner selection, early outsourcing decisions help determine whether a medicine can reach patients at a cost the market can sustain. | |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| How CDMOs Influence Late-Stage Development Success | Article | By Sam Wood and Suparna Sanyal, Lonza | Late-stage viral vector programs leave no margin for error. Regulatory, operational, and market pressures shape the path to commercial launch, and the choice of manufacturing partner carries weight. |
|
|
| Translating Engineered AAV Capsids Into Manufacturable Gene Therapies | White Paper | By Jacob Smith, Sabrina Triffault, Laurence Jeanson-Leh, et al., Viralgen | Engineered AAV capsids offer improved targeting and efficiency but introduce manufacturing, analytical, immunogenicity, and regulatory complexities requiring early, integrated development strategies. |
|
|
|
|
|
| Comparing Gel, qPCR & HPLC For DNA/RNA Analysis | Poster | By Delicia Henriques, Ph.D., Murali Jujjavarapu, Ryan Rubino, et al., ProBio | Cost-effective agarose gel electrophoresis offers reliable plasmid supercoil and host DNA/RNA quantification, providing a practical alternative to qPCR and HPLC for biomanufacturing quality control. |
|
|
| The Economic Case For Continuous Manufacturing | Article | By Aaron B. Cowley, Ph.D., Recipharm Advanced Bio | Assimilate how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies. |
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
